1. A phase I trial of ISIS 2503, an antisense inhibitor of H-ras in combination with gemcitabine in patients with advanced cancer;Adjei;Proc Am Soc Clin Oncol,2000
2. A phase I trial of an antisense oligonucleotide targeted to protein kinase C-α (ISIS 3521/ISI641A) delivered as a 24-hour continuous infusion (CI);Advani;Proc Am Soc Clin Oncol,1999
3. Coagulation and complement effects of an antisense phosphorothioate oligonucleotide targeting protein kinase C-α (ISIS 3521) are schedule and dose dependent;Advani;Proc Am Soc Clin Oncol,1990
4. Protection of hu-PBL-SCID/beige mice from HIV-1 infection by a 6-mer modified oligonucleotide, R-95288;Agatsuma;Antiviral Res,1997
5. Anti-human immunodeficiency virus type 1 activity of phosphodiester hexadeoxyribonucleotide modified by dibenzyloxybenzyl and hydroxyethyl residues at the 5′- and 3′-ends, R-95288;Agatsuma;Antivir Chem Chemother,1997